ASP0113

**ASP0113** is an investigational bivalent therapeutic **plasmid DNA vaccine** for prevention of cytomegalovirus infection, reactivation, and CMV disease in immunocompromised transplant recipients. Originally developed by Vical and licensed to Astellas, it contains two plasmids encoding human cytomegalovirus glycoprotein B and tegument phosphoprotein 65, intended to induce CMV-specific humoral and cellular immune responses after intramuscular administration. The program reached Phase 3 in CMV-seropositive recipients of allogeneic hematopoietic cell transplants, but the HELIOS study did not meet its primary or secondary efficacy endpoints; the ASP0113 program was subsequently terminated. ([thelancet.com](https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370%2821%2900067-5/fulltext))

Brand names

TransVax

Other names

CMVpp65/gB plasmid vaccine